Citation

BibTex format

@article{Evans:2026:10.1038/s41416-026-03488-w,
author = {Evans, TRJ and Cook, N and El-Khoueiry, A and Pinato, DJ and Tran, NH and Hsiehchen, D and Mena, E and Meyer, T and Wu, J and Pathak, SM and Paoletti, C and Dutta, L and Okpara, CE and Lopez, JS},
doi = {10.1038/s41416-026-03488-w},
journal = {British Journal of Cancer},
title = {A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms},
url = {http://dx.doi.org/10.1038/s41416-026-03488-w},
year = {2026}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <jats:title>Abstract</jats:title>                  <jats:sec>                    <jats:title>Background</jats:title>                    <jats:p>We present data from the Phase 1 open-label Study 101 of E7386, an oral protein-protein interaction inhibitor reported to block the CBP/β-catenin interaction, in patients with solid tumours.</jats:p>                  </jats:sec>                  <jats:sec>                    <jats:title>Methods</jats:title>                    <jats:p>                      Eligible patients (across the UK and US) aged ≥18 years had advanced/recurrent solid tumours (dose-escalation) or                      <jats:italic>CTNNB1</jats:italic>                      -mutated hepatocellular carcinoma (dose-expansion). Primary objectives were to assess safety/tolerability and determine the recommended Phase 2 dose (RP2D) of E7386.                    </jats:p>                  </jats:sec>                  <jats:sec>                    <jats:title>Results</jats:title>                    <jats:p>                      Thirty-eight patients received study drug (dose-escalation:                      <jats:italic>n</jats:italic>                       = 32; expansion:                      <jats:italic>n</jats:italic>                       = 6; dose-range: 5–120 mg twice daily [BID]); 60.5% received ≥3 prior anticancer medications. Dose-limiting toxicities (grade-2 lethargy and grade-2 decreased appetite) occurred in 1 patient (20 mg BID cohort). The RP2D was determined as 120 mg BID. Most (94.7%) patients experienced treatment-related adverse events (TRAEs), most frequently nausea (65.8%) and vomiting (60.5%), which were primarily grade 1/2 and well-managed with antiemetics. No grade 4/5 TRAEs were noted. Pharmacokinetic exposure increased with increasi
AU  - Evans,TRJ
AU  - Cook,N
AU  - El-Khoueiry,A
AU  - Pinato,DJ
AU  - Tran,NH
AU  - Hsiehchen,D
AU  - Mena,E
AU  - Meyer,T
AU  - Wu,J
AU  - Pathak,SM
AU  - Paoletti,C
AU  - Dutta,L
AU  - Okpara,CE
AU  - Lopez,JS
DO  - 10.1038/s41416-026-03488-w
PY  - 2026///
SN  - 0007-0920
TI  - A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms
T2  - British Journal of Cancer
UR  - http://dx.doi.org/10.1038/s41416-026-03488-w
UR  - https://doi.org/10.1038/s41416-026-03488-w
ER  -
Download